JPWO2021071806A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021071806A5 JPWO2021071806A5 JP2022546589A JP2022546589A JPWO2021071806A5 JP WO2021071806 A5 JPWO2021071806 A5 JP WO2021071806A5 JP 2022546589 A JP2022546589 A JP 2022546589A JP 2022546589 A JP2022546589 A JP 2022546589A JP WO2021071806 A5 JPWO2021071806 A5 JP WO2021071806A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- pharma
- cycloalkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 150000001602 bicycloalkyls Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 125000005348 fluorocycloalkyl group Chemical group 0.000 claims 3
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000002661 Spondylitis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- -1 spiroalkyl Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024187488A JP2025020196A (ja) | 2019-10-07 | 2024-10-24 | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911655P | 2019-10-07 | 2019-10-07 | |
| US62/911,655 | 2019-10-07 | ||
| PCT/US2020/054352 WO2021071806A1 (en) | 2019-10-07 | 2020-10-06 | Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187488A Division JP2025020196A (ja) | 2019-10-07 | 2024-10-24 | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022551197A JP2022551197A (ja) | 2022-12-07 |
| JP2022551197A5 JP2022551197A5 (https=) | 2024-05-31 |
| JPWO2021071806A5 true JPWO2021071806A5 (https=) | 2024-05-31 |
| JP7578704B2 JP7578704B2 (ja) | 2024-11-06 |
Family
ID=75436854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546589A Active JP7578704B2 (ja) | 2019-10-07 | 2020-10-06 | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物 |
| JP2024187488A Pending JP2025020196A (ja) | 2019-10-07 | 2024-10-24 | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187488A Pending JP2025020196A (ja) | 2019-10-07 | 2024-10-24 | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230023559A1 (https=) |
| EP (1) | EP4041229A4 (https=) |
| JP (2) | JP7578704B2 (https=) |
| KR (1) | KR20220079880A (https=) |
| CN (1) | CN114727991B (https=) |
| AU (1) | AU2020363356A1 (https=) |
| BR (1) | BR112022006507A2 (https=) |
| CA (1) | CA3156982A1 (https=) |
| CL (1) | CL2022000802A1 (https=) |
| CO (1) | CO2022004305A2 (https=) |
| CR (1) | CR20220148A (https=) |
| DO (1) | DOP2022000068A (https=) |
| EC (1) | ECSP22027871A (https=) |
| IL (1) | IL291734A (https=) |
| JO (1) | JOP20220085A1 (https=) |
| MX (1) | MX2022004128A (https=) |
| PE (1) | PE20230177A1 (https=) |
| PH (1) | PH12022550832A1 (https=) |
| WO (1) | WO2021071806A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| CN116782894A (zh) * | 2020-10-06 | 2023-09-19 | D.E.肖研究有限责任公司 | 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物 |
| AR125994A1 (es) | 2021-05-28 | 2023-08-30 | De Shaw Res Llc | COMPUESTOS DE ESPIROINDOLINONA COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 |
| WO2023122325A2 (en) * | 2021-12-23 | 2023-06-29 | Regents Of The University Of Michigan | Meta anilide compounds and methods for use of the same to treat diseases and disorders |
| AU2023370498B2 (en) * | 2022-10-28 | 2026-01-22 | Shanghai Deep Potential Technology Co., Ltd. | Aryl heterocyclic kv1.3 inhibitor, preparation method therefor, and use thereof |
| AR133293A1 (es) * | 2023-07-18 | 2025-09-17 | Muna Therapeutics Aps | Antagonistas del canal de potasio kv1.3 |
| AR133292A1 (es) * | 2023-07-18 | 2025-09-17 | Muna Therapeutics Aps | Antagonistas del canal de potasio kv1.3 |
| WO2025029769A1 (en) | 2023-07-31 | 2025-02-06 | Eli Lilly And Company | Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same |
| CN117105996B (zh) * | 2023-10-24 | 2024-02-06 | 北京瑞博奥医药科技有限公司 | 一种脱氧核糖衍生物的制备的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| WO2006029182A2 (en) * | 2004-09-07 | 2006-03-16 | The La Jolla Institute For Molecular Medicine | Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases |
| AU2005294123C1 (en) | 2004-10-07 | 2010-01-21 | Vitae Pharmaceuticals, Inc. | Diaminoalkane aspartic protease inhibitors |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| WO2007117482A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
| WO2011073277A1 (en) * | 2009-12-16 | 2011-06-23 | Evotec Ag | PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS |
| WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| US9493451B2 (en) * | 2011-05-16 | 2016-11-15 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| ES2865199T3 (es) * | 2015-08-27 | 2021-10-15 | Pfizer | Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4 |
| US20170362228A1 (en) * | 2016-06-16 | 2017-12-21 | Genentech, Inc. | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| BR112018076258A2 (pt) * | 2016-06-30 | 2019-03-26 | Basilea Pharm Int Ag | inibidores mitocondriais para o tratamento de distúrbios de proliferação |
| EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| ES2986417T3 (es) * | 2018-08-13 | 2024-11-11 | Hoffmann La Roche | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa |
-
2020
- 2020-10-06 AU AU2020363356A patent/AU2020363356A1/en not_active Abandoned
- 2020-10-06 CN CN202080084382.4A patent/CN114727991B/zh active Active
- 2020-10-06 KR KR1020227013507A patent/KR20220079880A/ko active Pending
- 2020-10-06 CR CR20220148A patent/CR20220148A/es unknown
- 2020-10-06 CA CA3156982A patent/CA3156982A1/en active Pending
- 2020-10-06 BR BR112022006507A patent/BR112022006507A2/pt unknown
- 2020-10-06 US US17/766,885 patent/US20230023559A1/en active Pending
- 2020-10-06 WO PCT/US2020/054352 patent/WO2021071806A1/en not_active Ceased
- 2020-10-06 MX MX2022004128A patent/MX2022004128A/es unknown
- 2020-10-06 EP EP20874462.3A patent/EP4041229A4/en active Pending
- 2020-10-06 PH PH1/2022/550832A patent/PH12022550832A1/en unknown
- 2020-10-06 JP JP2022546589A patent/JP7578704B2/ja active Active
- 2020-10-06 PE PE2022000534A patent/PE20230177A1/es unknown
-
2022
- 2022-03-27 IL IL291734A patent/IL291734A/en unknown
- 2022-03-30 CL CL2022000802A patent/CL2022000802A1/es unknown
- 2022-03-31 DO DO2022000068A patent/DOP2022000068A/es unknown
- 2022-04-05 CO CONC2022/0004305A patent/CO2022004305A2/es unknown
- 2022-04-06 JO JOP/2022/0085A patent/JOP20220085A1/ar unknown
- 2022-04-07 EC ECSENADI202227871A patent/ECSP22027871A/es unknown
-
2024
- 2024-10-24 JP JP2024187488A patent/JP2025020196A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021071806A5 (https=) | ||
| DE60003709T2 (de) | Substituierte azole | |
| FR2692893A1 (fr) | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. | |
| JPH09509171A (ja) | 免疫抑制活性を有するミコフェノール酸の４−アミノ誘導体 | |
| JP2015502387A5 (https=) | ||
| DK157545B (da) | Analogifremgangsmaade til fremstilling af 4-fenyl-1-hydroxyalkylimidazolderivater eller farmaceutisk acceptable syreadditionssalte deraf | |
| JPWO2021071802A5 (https=) | ||
| DE69006907T2 (de) | Arylthiazolylimidazole als 5HT3-Antagonisten. | |
| JP2024522718A (ja) | 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物 | |
| JPWO2021071821A5 (https=) | ||
| UA73125C2 (uk) | Похідні амінотіазолу, спосіб їх одержання, фармацевтична композиція та їх використання як лігандів рецептора crf | |
| JP2024072283A5 (https=) | ||
| MA28117A1 (fr) | Procédé pour la préparation de composés hétérocycliques à substitution N-amino | |
| DE69026087T2 (de) | Substituierte 2-imidazoline und verfahren zur herstellung sowie deren verwendung | |
| JPWO2022076285A5 (https=) | ||
| JPWO2021071803A5 (https=) | ||
| JPWO2020247447A5 (https=) | ||
| DE69502380T2 (de) | 4-aminoderivate von 5-substituierten mycophenolsäuren | |
| JPWO2021231572A5 (https=) | ||
| US4845231A (en) | Tetrazoles and their use as hypoglycemic agents | |
| DE19842833A1 (de) | 2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung | |
| DE3883891T2 (de) | Benzimidazol-Derivate und Verfahren zu deren Herstellung. | |
| JPWO2020247445A5 (https=) | ||
| JPH01265092A (ja) | ピリドン系抗菌剤 | |
| JPWO2021071812A5 (https=) |